#kidney disease

2 stories

Research April 5, 2026 · View digest

Beyond Weight Loss: GLP-1 Drugs Target Heart Failure, Kidney Disease, and Addiction

The FLOW trial showed semaglutide reduced major kidney disease events by ~24%, while the SELECT trial found a 20% reduction in major adverse cardiovascular events among 17,600+ adults.

Clinical Trials April 2, 2026 · View digest

APhA2026 Highlights GLP-1 Expansion into Kidney Disease and Sleep Apnea

At APhA2026, semaglutide's FLOW trial showed 24% reduction in major kidney events in CKD patients, while tirzepatide's SURMOUNT-OSA trial demonstrated dramatic reductions in sleep apnea severity.